Charlotte's Web posts margin recovery, SG&A cuts; still loss, cash and debenture risks

Quick snapshot - Charlotte's Web Holdings, Inc. (OTCBB: CWBHF)

All dollar amounts below are reported in thousands, except share and per‑share data, unless otherwise noted.

Key facts & headline numbers (Q2 2025 / Six months 2025)
- Revenue: $12,806 (Q2 2025) vs $12,289 (Q2 2024) - +4.2%; Six months $25,068 vs $24,413 - +2.7%
- Gross profit: $5,990 (Q2 2025) vs $2,582 (Q2 2024) - Q2 gross margin 46.8% vs 21.0%; Six months gross profit $12,220 - margin 48.7% vs 38.9%
- Cost of goods sold: $6,816 (Q2 2025) vs $9,707 (Q2 2024) - down 29.8% (prior-year quarter included a $3.8M inventory provision)
- Selling, general & administrative expense: $10,062 (Q2 2025) vs $14,727 (Q2 2024) - down 31.7%
- Operating loss: $(4,072) (Q2 2025) vs $(12,145) (Q2 2024)
- Net loss: $(6,288) (Q2 2025) vs $(11,057) (Q2 2024); basic EPS $(0.04) vs $(0.07) - Six months net loss $(12,500) vs $(20,691)
- Cash & cash equivalents: $15,268 at June 30, 2025 (vs $22,618 at Dec 31, 2024)
- Total assets: $87,976 (June 30, 2025) vs $113,442 (Dec 31, 2024)
- Total liabilities: $73,047 (June 30, 2025); Convertible debenture net carrying amount $48,616 (principal $62,962)
- Shares outstanding: 158,617,767 (June 30, 2025); 159,136,454 reported outstanding Aug 12, 2025

Positives inside the company (what's working)
- Revenue growth: modest year‑over‑year increases in product revenue (Q2 +4.2%; six months +3.7%) driven by new product lines (CBN Sleep gummies, CBG Focus, mushroom gummies, Brightside low‑THC).
- Margin recovery: Gross margin jumped to 46.8% Q2 (48.7% YTD) largely because prior‑year inventory impairment did not recur - a meaningful improvement in product economics.
- Expense discipline: SG&A reduced ~28-32% vs prior periods, helped by termination of the MLB rights obligation (removes ~$18M future payments) and lower amortization expense (~$1.9M benefit) plus headcount and operating efficiency actions.
- Strategic R&D progress: DeFloria (joint venture) advanced - FDA cleared Phase 2 trial for AJA001 (botanical candidate for ASD symptoms). That is a strategic asset with upside if clinical progress continues.
- Reduced cash burn vs prior year: Net cash used in operations $6,786 (six months 2025) vs $11,883 (six months 2024).

Negatives / risks (what to watch)
- Still unprofitable: Q2 net loss $(6.3M) and YTD $(12.5M); accumulated deficit $314,069.
- Cash & liquidity: Cash fell to $15.3M; operating losses and debt servicing create mid‑term financing risk if revenue or cost improvements stall.
- Large convertible debenture: Debenture net carry $48,616 (principal $62,962) convertible at C$2.00; foreign currency remeasurement produced a $2.6M loss in Q2 - this instrument creates earnings volatility and potential dilution on conversion.
- Fair‑value volatility: Change in fair value of financial instruments was a loss $(1.543M) in Q2 (primarily DeFloria investment remeasurement) - the DeFloria investment is Level 3 and highly subjective, producing material earnings swings.
- Other income/expense swings: Q2 other income (expense) net $(675) despite a $2.326M gain recognized on termination of MLB rights - foreign exchange and other items offset gains.
- Inventory & operations: Inventory still $19,398 with a $966 provision; in‑house gummy production startup increased variable costs and may pressure margins until fully scaled.
- Regulatory & market risk: New state regulations (THC/CBD limits, labeling/testing) could require reformulations and add costs; federal CBD regulation timing remains uncertain and affects the debenture interest feature and market opportunity.

Operational & strategic takeaways - concise
- Management cut costs and removed a large license obligation (MLB) - this materially reduced SG&A and improved near‑term cash flow dynamics.
- Core product revenue is stable and expanding into adjacent botanicals; gross margins improved materially but are partly a one‑time benefit of not repeating a prior inventory charge.
- Key near‑term risk is funding: cash is limited (~$15.3M) versus continuing operating losses and a material convertible debenture on the balance sheet. The company may need to access capital markets or debt if results don't continue improving.
- DeFloria progress (FDA Phase 2 clearance) is a strategic positive but currently adds valuation volatility via fair‑value accounting.

What to watch next
- Quarterly cash burn and updated cash runway disclosures.
- Any capital raises, debt amendments, or conversions related to the convertible debenture.
- Further DeFloria clinical milestones and related fair‑value impacts.
- Impact of state regulatory changes on sales, product formulations, or margins.
- Execution of in‑house gummy manufacturing (scale and margin improvement).

Bottom line: Charlotte's Web (CWBHF) shows operational progress - higher gross margins and lower SG&A after terminating an expensive MLB deal - but remains unprofitable, with limited cash, a large convertible debenture, and fair‑value volatility tied to its DeFloria investment. The company's strategic thesis now hinges on continued margin recovery, successful commercialization of new botanical products, and either improved cash generation or access to new capital.